Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
167 pending office actions • 96 clients • 143 examiners • 65 art units • 0 of 167 (0%) have an AI response strategy ready
Clark+Elbing LLP specializes in the Biotechnology & Pharmaceuticals technology area, having filed 8984 career applications. The firm is currently managing 131 pending office actions, which reflects their ongoing prosecution efforts. This total of 8984 career applications provides a broad context for their work in the life sciences sector. The firm's activity in Biotechnology & Pharmaceuticals is a central component of their professional profile.
The resolved allowance rate for the firm stands at 67.87 percent, based on their 8984 career applications. This 67.87 percent rate offers a data point for the likelihood of obtaining an allowance in this technical field. On average, the firm experiences 3.89 office actions per allowance. This 3.89 average informs practitioners about the typical duration and intensity of the prosecution process. With 131 pending office actions, the firm continues to navigate the patent office's requirements. The combination of a 67.87 percent allowance rate and a 3.89 office action average characterizes their historical performance in Biotechnology & Pharmaceuticals.
Based on the USPTO statutory response window for each pending office action. 53 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 53 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (1%) |
| §101 + other | 18 (11%) |
| §103 only | 37 (22%) |
| §102 only | 4 (2%) |
| §112 only | 15 (9%) |
| Double-patenting only | 2 (1%) |
| Double-patenting + other | 21 (13%) |
| Multi-statute (no §101) | 68 (41%) |
| No statute on record | 1 (1%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, KHOA NHAT | 3 | 43.2% | +53.3% |
| NEAGU, IRINA | 3 | 46.8% | +57.3% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 3 | 33.3% | +38.9% |
| COFFA, SERGIO | 3 | 61.1% | +32.5% |
| REYNOLDS, FRED H | 3 | 33.0% | +39.2% |
| KAUFMAN, CLAIRE M | 3 | 63.5% | +50.7% |
| FAN, WEIHUA | 2 | 83.4% | +12.6% |
| PETTITT, JOHN F | 2 | 26.0% | +21.8% |
| LEE, ANDREW P | 2 | 48.3% | +23.1% |
| DAHLE, CHUN WU | 2 | 50.2% | +51.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18709255 | BACTERIAL STRAINS FOR TREATING DISEASE | FAN, WEIHUA | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629918 | ADOPTIVE TRANSFER OF PLASMACYTOID DENDRITIC CELLS TO PREVENT OR TREAT HAIR LOSS | MIANO, JOSEPH PAUL | 134d overdue |
| 18024179 | METHODS FOR IDENTIFYING CROSS-MODAL FEATURES FROM SPATIALLY RESOLVED DATA SETS | TRAN, DUY ANH | 132d overdue |
| 18818268 | ANTIBODIES WITH FC MODIFICATIONS AND METHODS OF USING THE SAME | GUSTILO, ESTELLA M | 72d overdue |
| 18165613 | CELL MEMBRANE PENETRATING CONJUGATES | VARADARAJ, ARCHANA | 56d overdue |
| 17440081 | CARDIOMYOCYTE PROLIFERATION | TRAN, KHOA NHAT | 37d overdue |
| 18039812 | RNA-TARGETING COMPOSITIONS AND METHODS FOR TREATING MYOTONIC DYSTROPHY TYPE 1 | VIJAYARAGHAVAN, JAGAMYA NMN | 31d overdue |
| 17629313 | PEPTIDE HAVING HAIR GROWTH PROMOTING ACTIVITY, AND USE THEREOF | NIEBAUER, RONALD T | 3d overdue |
| 18024624 | PEPTIDES ENDOWED WITH ANGIOGENIC ACTIVITY | KONOPELSKI SNAVEL, SARA ELIZABETH | 5d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17440081 | CARDIOMYOCYTE PROLIFERATION | TRAN, KHOA NHAT | 37d overdue |
| 17800639 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | LEE, ANDREW P | 19d overdue |
| 17748323 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN NEURAL PROGENITOR CELLS | TRAN, KHOA NHAT | 10d overdue |
| 17637392 | COMPSTATIN ANALOGUES AND THEIR MEDICAL USES | COFFA, SERGIO | 3d overdue |
| 18024624 | PEPTIDES ENDOWED WITH ANGIOGENIC ACTIVITY | KONOPELSKI SNAVEL, SARA ELIZABETH | 5d |
| 18061755 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE | DAHLE, CHUN WU | 7d |
| 17413223 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS ACROSS THE ROUND WINDOW MEMBRANE | REYNOLDS, FRED H | 28d |
| 18140141 | METHODS OF TREATING LYMPHOPENIA | KAUFMAN, CLAIRE M | 60d |
| Art Unit | Apps |
|---|---|
| 1658 | 10 |
| 1632 | 9 |
| 1629 | 5 |
| 1631 | 5 |
| 1633 | 4 |
| 1654 | 4 |
| 1674 | 4 |
| 1663 | 3 |
| 3991 | 3 |
| 1637 | 3 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19388128 | DEVICES FOR KYPHOPLASTY AND METHODS OF USE THEREOF | Translational And Fundamental Technologies Institute LLC | GREEN, MICHELLE CHRISTINE | 3773 | §103 | Final Rejection | — | Pending | Nov 13, 2025 |
| 19162601 | MODIFIED NUCLEIC ACID SEQUENCE FOR CONFERRING CLUBROOT RESISTANCE TO CANOLA AND METHODS OF PRODUCING SAME | The Governors of the University of Alberta | FAN, WEIHUA | 1663 | §101§102§112 | Non-Final OA | — | Pending | Sep 05, 2025 |
| 19312085 | RECOMBINANT ADENOVIRUSES AND USE THEREOF | Washington University | DRISCOLL, LORA E BARNHART | 3991 | §101DP | Non-Final OA | — | Pending | Aug 27, 2025 |
| 19289942 | METHODS AND COMPOSITIONS FOR TREATING EPILEPSY | Uniqure France | QIAN, CELINE X | 1637 | §102DP | Non-Final OA | — | Pending | Aug 04, 2025 |
| 19265435 | COMPOUNDS AND METHODS FOR TREATING MUSCULAR DYSTROPHY AND OTHER DISORDERS | The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health | DIAMOND, ALAN D | 3991 | DP | Non-Final OA | — | Pending | Jul 10, 2025 |
| 19126720 | ELECTRONICALLY ENABLED PILL ORGANIZER | 9494-1861 Québec Inc. | MCCORMACK, THOMAS S | 2686 | §103 | Non-Final OA | — | Pending | May 02, 2025 |
| 19181929 | COMPOSITIONS AND METHODS FOR INDUCING OOCYTE MATURATION | Gameto, Inc. | CORDAS, EMILY ANN | 1632 | §102§103Other | Non-Final OA | — | Pending | Apr 17, 2025 |
| 19060439 | CULTURE MEDIA AND CONDITIONS FOR IN VITRO EXPANSION OF HEPATOCYTES | Satellite Biosciences, Inc. | TRAN, KHOA NHAT | 1632 | §102§103 | Final Rejection | — | Pending | Feb 21, 2025 |
| 18876576 | COMPOSITIONS AND METHODS FOR THE PURIFICATION OF SQUALENE | Amyris, Inc. | FADHEL, ALI Z | §102§103 | Non-Final OA | — | Pending | Dec 18, 2024 | |
| 18980973 | MULTISENSOR BRACELET | Legionarius, LLC | HUNNINGS, TRAVIS R | 2689 | §102§103 | Non-Final OA | 22d | Pending | Dec 13, 2024 |
| 18853473 | ADENO-ASSOCIATED VIRUS POTENCY ASSAY AND USES THEREOF | Astellas Gene Therapies, Inc. | POPA, ILEANA | §103 | Non-Final OA | — | Pending | Oct 02, 2024 | |
| 18850703 | THERAPEUTIC USES OF BRADYKININ B2-RECEPTOR ANTAGONISTS | Pharvaris GmbH | ROZOF, TIMOTHY R | 1629 | §102§112DP | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18826883 | METHODS, COMPOSITIONS AND SYSTEMS FOR SOLID-STATE BAROCALORIC APPLICATIONS | President and Fellows of Harvard College | PETTITT, JOHN F | 3763 | §103§112 | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18843373 | GPR120 AGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | Dompe' Farmaceutici Spa | REDWOOD, CHRISTOPHER EVAN | §103§112DP | Non-Final OA | — | Pending | Sep 03, 2024 | |
| 18821656 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA | Minerva Neurosciences, Inc. | RODRIGUEZ, RAYNA B | DP | Non-Final OA | — | Pending | Aug 30, 2024 | |
| 18818268 | ANTIBODIES WITH FC MODIFICATIONS AND METHODS OF USING THE SAME | The General Hospital Corporation | GUSTILO, ESTELLA M | 1646 | §103§112Other | Final Rejection | 72d overdue | Pending | Aug 28, 2024 |
| 18841472 | ORAL PCLX-001 IN THE TREATMENT OF HUMAN CANCER | Pacylex Pharmaceuticals Inc. | CORNET, JEAN P | §102§103§112 | Non-Final OA | — | Pending | Aug 26, 2024 | |
| 18838347 | NEURAL PROGENITOR CELL COMPOSITIONS AND METHODS OF USING THE SAME | The General Hospital Corporation | KASAYAN, KATRIEL BARCELLANO | §101§103§112 | Non-Final OA | — | Pending | Aug 14, 2024 | |
| 18572977 | DEXMECAMYLAMINE AND USES THEREOF | Atacama Therapeutics, Inc. | ROCHELLE, CIERRA MARIE | §103 | Non-Final OA | — | Pending | Aug 13, 2024 | |
| 18833242 | IMIDAZOPYRIDINE INHIBITORS OF TYROSINE KINASE | Bridgene Biosciences. Inc. | FETTEROLF, BRANDON J | §112 | Non-Final OA | — | Pending | Jul 25, 2024 | |
| 18769009 | RAS INHIBITORS | Revolution Medicines, Inc. | KIM, SEONG JONG | §112 | Non-Final OA | — | Pending | Jul 10, 2024 | |
| 18764714 | METHODS OF USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT DEPRESSION | Minerva Neurosciences, Inc. | NEAGU, IRINA | §103§112 | Non-Final OA | — | Pending | Jul 05, 2024 | |
| 18724352 | PEPTIDE HAVING ACTIVITY OF IMPROVING STATE OF SKIN, AND USE THEREOF | Caregen Co., Ltd. | KONOPELSKI SNAVEL, SARA ELIZABETH | §101§112 | Non-Final OA | — | Pending | Jun 26, 2024 | |
| 18724255 | PEPTIDE HAVING ACTIVITY OF IMPROVING STATE OF SKIN, AND USE THEREOF | Caregen Co., Ltd. | COFFA, SERGIO | 1658 | §102§112 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18724295 | PEPTIDE HAVING ACTIVITY OF IMPROVING STATE OF SKIN, AND USE THEREOF | Caregen Co., Ltd. | HA, JULIE | §101 | Non-Final OA | — | Pending | Jun 26, 2024 | |
| 18719261 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS | Alexion Pharmaceuticals, Inc. | BAUER, BRIANNA LEE | §112 | Non-Final OA | — | Pending | Jun 13, 2024 | |
| 18719260 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | Alexion Pharmaceuticals, Inc. | ROMERO, KRISTEN WANG | §102§103Other | Non-Final OA | — | Pending | Jun 13, 2024 | |
| 18714669 | METHOD OF GENERATING FUNCTIONAL ISLETS FROM PLURIPOTENT STEM CELLS | Hangzhou Reprogenix Bioscience, Inc. | MOSS, NATALIE M | §103§112 | Non-Final OA | — | Pending | May 30, 2024 | |
| 18709255 | BACTERIAL STRAINS FOR TREATING DISEASE | Microba Ip Pty Ltd. | FAN, WEIHUA | 1663 | §112 | Final Rejection | — | Pending | May 10, 2024 |
| 18659831 | PHARMACEUTICAL COMBINATIONS FOR TREATMENT OF HBV | Hoffmann-La Roche, Inc. | KONOPKA, CATHERINE ANNE | §102§103§112 | Non-Final OA | — | Pending | May 09, 2024 | |
| 18708275 | FLUID TREATMENT SYSTEM AND RELATED METHODS | Lignosol Ip Limited | BUSHEY, CHARLES S | 1776 | §102§103§112 | Non-Final OA | — | Pending | May 08, 2024 |
| 18658154 | SYSTEM FOR DETECTING MICRO-NEUROMAS AND METHODS OF USE THEREOF | President and Fellows of Harvard College | SIPES, JOHN CURTIS | 2872 | Other | Non-Final OA | — | Pending | May 08, 2024 |
| 18655854 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | Thomas Jefferson University | LEE, ANDREW P | 1691 | §102§103 | Non-Final OA | — | Pending | May 06, 2024 |
| 18653106 | METHODS OF TREATING CANCER | Inspirna, Inc. | HUTTER, GILLIAN A | 1625 | §103DP | Non-Final OA | — | Pending | May 02, 2024 |
| 18706302 | DETECTION, STAGING, MONITORING AND TREATING A DISEASE OR A CONDITION | Sunbird Bio, Inc. | BOWERS, ERIN M | 1653 | §102Other | Non-Final OA | 20d | Pending | Apr 30, 2024 |
| 18647374 | SIGMA LIGAND COMPOUNDS AND USES THEREOF | Minerva Neurosciences, Inc. | RICCI, CRAIG D | §112 | Non-Final OA | — | Pending | Apr 26, 2024 | |
| 18645535 | FUNCTIONAL EEG MONTAGE FOR COGNITIVE SKILL DEVELOPMENT | Thynk, Inc. | JANG, CHRISTIAN Y | §103§112 | Non-Final OA | — | Pending | Apr 25, 2024 | |
| 18646092 | ENGINEERED TISSUE CONSTRUCTS AND USES THEREOF | Satellite Biosciences, Inc. | PELLEGRINO, BRIAN E | §102§103§112Other | Non-Final OA | — | Pending | Apr 25, 2024 | |
| 18704122 | CULTURE MEDIA AND CONDITIONS FOR IN VITRO EXPANSION AND/OR MATURATION OF HEPATOCYTES | Satellite Biosciences, Inc. | GU, QINHUA | 1633 | §102§103§112Other | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18634241 | GONADOTROPIN-RELEASING HORMONE ANTAGONIST DOSING REGIMENS FOR THE TREATMENT OF ENDOMETRIOSIS | Kissei Pharmaceutical Co., Ltd. | HUI, SAN MING R | §103DP | Non-Final OA | — | Pending | Apr 12, 2024 | |
| 18634289 | CRYSTALLINE FORMS OF RAS INHIBITORS, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USE THEREOF | Revolution Medicines, Inc. | INAM, SAHAR | 1622 | §103 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18698176 | OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING INFLAMMATORY LUNG DISEASES | DSM Nutritional Products, LLC | LAU, JONATHAN S | §102§103§112DP | Non-Final OA | — | Pending | Apr 03, 2024 | |
| 18693722 | PLATFORMS FOR DRUG TESTS AGAINST SYNUCLEINOPATHY USING HUMAN BRAIN ORGANOIDS | Okinawa Institute Of Science And Technology School Corporation | ROGERS, ERIC JASON | 1638 | §102§103§112 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18605744 | ASSAYS FOR ALPHA-DYSTROGLYCAN GLYCOSYLATION AND METHODS FOR USING SAME | Bridgebio Services Inc. | MONTGOMERY, ANN Y | §101§103§112 | Non-Final OA | — | Pending | Mar 14, 2024 | |
| 18691738 | SYNERGISTIC NANOMEDICINE DELIVERING TOPOISOMERASE I TOXIN (SN-38) AND INHIBITORS OF POLYNUCLEOTIDE KINASE 3'-PHOSPHATASE (PNKP) FOR ENHANCED TREATMENT OF COLORECTAL CANCER | The Governors of the University of Alberta | PROSSER, ALISSA J | 1619 | §103§112 | Non-Final OA | 53d | Pending | Mar 13, 2024 |
| 18691764 | SORBENTS AND METHODS FOR CARBON CAPTURE VIA CALCIUM LOOPING | UTI LIMITED PARTNERSHIP | HAILEY, PATRICIA L | §102§112 | Non-Final OA | — | Pending | Mar 13, 2024 | |
| 18602622 | GENE THERAPY FOR TUBEROUS SCLEROSIS | The General Hospital Corporation | VIVLEMORE, TRACY ANN | §102§112DP | Non-Final OA | — | Pending | Mar 12, 2024 | |
| 18690028 | PROCESS FOR FORMULATING COMPOSITIONS COMPRISING GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | Zealand Pharma A/S | REYNOLDS, FRED H | §102§103§112DP | Non-Final OA | — | Pending | Mar 07, 2024 | |
| 18688518 | METHODS FOR IDENTIFYING CROSS-MODAL FEATURES FROM SPATIALLY RESOLVED DATA SETS | The General Hospital Corporation | RIVERA-MARTINEZ, GUILLERMO M | 2677 | §112 | Final Rejection | 22d overdue | Pending | Mar 01, 2024 |
| 18688617 | METHODS OF PRODUCING HUMAN MILK OLIGOSACCHARIDES AND COMPOSITIONS THEREOF | Amyris, Inc. | MOEHLMAN, ANDREW TERRY | 1655 | §103§112 | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18688026 | DOSAGE REGIME | Zealand Pharma A/S | COFFA, SERGIO | §103 | Final Rejection | — | Pending | Feb 29, 2024 | |
| 18686817 | ANTI-CLDN-18.2 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Shanghai Junshi Biosciences Co., Ltd. | CHATTIN, AMY MARIE | §112DP | Non-Final OA | — | Pending | Feb 26, 2024 | |
| 18684449 | LONG-LIVED REDOX-ACTIVE MOLECULES WITH LOW REDOX POTENTIAL | President and Fellows of Harvard College | KOROVINA, ANNA | §102§103 | Non-Final OA | — | Pending | Feb 16, 2024 | |
| 18684014 | COMPOSITIONS CONTAINING POLYNUCLEOTIDE AMPHIPHILES AND METHODS OF USE THEREOF | Elicio Therapeutics, Inc. | HUDSON, AMY ROSE | §102§103§112 | Non-Final OA | — | Pending | Feb 15, 2024 | |
| 18683728 | PREPARATION OF LIBRARIES OF PROTEIN VARIANTS EXPRESSED IN EUKARYOTIC CELLS | Iontas Limited | FLINDERS, JEREMY C | §102§103§112 | Non-Final OA | — | Pending | Feb 14, 2024 | |
| 18681396 | SALT TOLERANT PLANTS | Rory James Hornby | PAGE, BRENT T | 1663 | §112 | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18427351 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE | Invetx, Inc. | DAHLE, CHUN WU | §102§112 | Non-Final OA | — | Pending | Jan 30, 2024 | |
| 18577369 | COMPOSITIONS AND METHODS FOR ACTIVATING A NEURAL RECEPTOR | Gila Therapeutics, Inc. | CHERNYSHEV, OLGA N | §101§102§112DP | Non-Final OA | — | Pending | Jan 08, 2024 | |
| 18396160 | POLYPEPTIDES WITH ALTERED BINDING TO NEONATAL FC RECEPTOR (FCRN) AND METHODS OF USE | Invetx, Inc. | BENAVIDES, JENNIFER ANN | §103DP | Non-Final OA | — | Pending | Dec 26, 2023 | |
| 18574221 | MIGRATION OF HUMAN PERIPHERAL LEUKOCYTES IN RESPONSE TO CHEMOTACTIC FACTORS DURING PREGNACY | The Governors of the University of Alberta | OGUNTADE, ELIZABETH BISOLA | 1654 | §101§103§112DP | Non-Final OA | — | Pending | Dec 26, 2023 |
| 18393145 | Preparation Method and Enrichment Method for Cyanidin-3-Diglucoside-5-Glucoside | China Agricultural University | SWIFT, CANDICE LEE | 1657 | §103§112Other | Final Rejection | 22d | Pending | Dec 21, 2023 |
| 18571567 | PRODUCTION OF HALOGENATED ALKOXYETHANE | Commonwealth Scientific And Industrial Research Organisaton | BAHTA, MEDHANIT W | §102§103 | Non-Final OA | — | Pending | Dec 18, 2023 | |
| 18571585 | SYNTHESIS OF HALOGENATED ALKOXYETHANE | Commonwealth Scientific And Industrial Research Organisation | MURESAN, ANA Z | §103 | Non-Final OA | — | Pending | Dec 18, 2023 | |
| 18516366 | PROTEIN PROSTHESES FOR MITOCHONDRIAL DISEASES OR CONDITIONS | The General Hospital Corporation | WEHBE, ANNE MARIE SABRINA | 1634 | §112 | Final Rejection | — | Pending | Nov 21, 2023 |
| 18561964 | METHODS OF ENRICHING FOR CIRCULAR POLYRIBONUCLEOTIDES | Flagship Pioneering Innovations Vi, LLC | RAVINDRA, KRISHNA NUGGEHALLI | §103§112 | Non-Final OA | — | Pending | Nov 17, 2023 | |
| 18289801 | COMBINATION OF PRAME SPECIFIC T CELL RECEPTORS AND CHIMERIC CO-STIMULATORY RECEPTORS | Medigene Immunotherapies GmbH | BUNNER, BRIDGET E | 1647 | §103DP | Non-Final OA | — | Pending | Nov 07, 2023 |
| 18288870 | KETAMINE AND CANNABIS FOR THE TREATMENT OF EMOTIONAL DISORDERS | Progressive Therapeutics Inc. | MELLER, MICHAEL V | 1655 | §102§103 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18012400 | CULTURE OF ORGANOIDS | Genome Research Limited | PAULUS, ERIN VIRGINIA | 1631 | §102§103§112 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18288239 | ULTRA-STRONG HYDROGEL FIBERS | UTI LIMITED PARTNERSHIP | JONES, KOLTON ED | 1763 | §103§112 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18287963 | TISSUE-TARGETED MODIFIED AAV CAPSIDS AND METHODS OF USE THEREOF | Astellas Gene Therapies, Inc. | ALLEN, MICHAEL D | 1671 | §103§112 | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18287793 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTIONS | The Queensland Institute of Medical Research | BANERJEE, KOYELI | 1658 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18030740 | BIOFACTORS FOR THE TREATMENT AND PROPHYLAXIS OF DEMENTIA | Wörwag Pharma GmbH & Co.Kg | CHANDRAKUMAR, NIZAL S | 1625 | §103 | Non-Final OA | — | Pending | Oct 16, 2023 |
| 18285899 | METHODS, COMPOSITIONS AND SYSTEMS FOR SOLID-STATE BAROCALORIC APPLICATIONS | President and Fellows of Harvard College | PETTITT, JOHN F | 3763 | §102§103§112 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18285697 | LIGNIN-BASED COMPOSITIONS AND RELATED HEAVY METAL RECOVERY METHODS | Lignosol Ip Limited | ZHANG, KELING NMN | 1732 | §103§112 | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18282443 | MEC SYSTEM | Electrochaea GmbH | KEELING, ALEXANDER W | §103 | Non-Final OA | — | Pending | Sep 15, 2023 | |
| 18281346 | COMPOSITIONS AND METHODS FOR TREATING X-LINKED MYOTUBULAR MYOPATHY | Audentes Therapeutics, Inc. | DITMER, KATHRYN ELIZABETH | 3785 | §103§112 | Non-Final OA | 19d | Pending | Sep 11, 2023 |
| 18244773 | GONADOTROPIN-RELEASING HORMONE ANTAGONIST DOSING REGIMENS FOR TREATING UTERINE FIBROIDS AND REDUCING MENSTRUAL BLOOD LOSS | Kissei Pharmaceutical Co., Ltd. | COPPINS, JANET L | 1628 | §103 | Non-Final OA | 22d | Pending | Sep 11, 2023 |
| 18281025 | PROFILING EPIGENETIC AGE IN SINGLE CELLS AND WITH LOW-PASS SEQUENCING DATA | The Brigham And Women'S Hospital, Inc. | ELKINS, BLAKE HARRISON | §101§103§112 | Non-Final OA | — | Pending | Sep 08, 2023 | |
| 18280325 | TREATMENT OF CORONAVIRUS INFECTIONS USING SAM CYCLE INHIBITORS | Technische Universität München | NEAGU, IRINA | 1629 | §102§103§112 | Non-Final OA | — | Pending | Sep 05, 2023 |
| 18279708 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | Dompe' Farmaceutici Spa | DAHLIN, HEATHER RAQUEL | 1629 | §102§103DP | Final Rejection | 15d | Pending | Aug 31, 2023 |
| 18279517 | THE USE OF EMPAGLIFLOZIN FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE | The Governors of the University of Alberta | SCHACHERMEYER, SAMANTHA LYNN | 1693 | §103 | Final Rejection | 46d overdue | Pending | Aug 30, 2023 |
| 18547164 | PHARMACEUTICAL COMPOSITIONS COMPRISING RANPIRNASE | Okogen, Inc. | SWIFT, CANDICE LEE | 1657 | §102§103§112DPOther | Non-Final OA | — | Pending | Aug 21, 2023 |
| 18275849 | NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES | Dompe' Farmaceutici Spa | FORD, VANESSA L | 1674 | §102§112 | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18228818 | COMPOSITE EMBOLIZATION BEADS | Translational And Fundamental Technologies Institute LLC | TRAN, LARA LINH | 3791 | §102§103 | Non-Final OA | — | Pending | Aug 01, 2023 |
| 18224138 | EARLY ADMINISTRATION OF LOW-DOSE COLCHICINE AFTER MYOCARDIAL INFARCTION | Institut De Cardiologie De Montreal | DAVIS, BRIAN J | 1614 | §103Other | Final Rejection | — | Pending | Jul 20, 2023 |
| 18273395 | ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES | The General Hospital Corporation | LEE, YIE CHIA | 1642 | §102§103§112Other | Non-Final OA | — | Pending | Jul 20, 2023 |
| 18273121 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | Tufts Medical Center, Inc. | WEHRHEIM, LINDSEY GAIL | 3799 | §102 | Non-Final OA | — | Pending | Jul 19, 2023 |
| 17910686 | GENE THERAPY OF NIEMANN-PICK DISEASE TYPE C | UCL Business Ltd | ABBOTT, KODYE LEE | 1634 | §103§112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18256304 | METHOD OF TREATING HEREDITARY HEMORRHAGIC TELANGIECTASIA USING PAZOPANIB | Hht Foundation International, Inc. | WORSHAM, JESSICA N | 1615 | §103 | Non-Final OA | 83d | Pending | Jun 07, 2023 |
| 18265178 | A FILTER UNIT, A TEXTILE TREATMENT APPARATUS, USE THEREOF AND A METHOD OF FILTERING MICROPARTICLES | Xeros Limited | SHAHINIAN, LEVON J | 1711 | §102§103 | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18039812 | RNA-TARGETING COMPOSITIONS AND METHODS FOR TREATING MYOTONIC DYSTROPHY TYPE 1 | Astellas Gene Therapies, Inc. | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §103§112 | Non-Final OA | 31d overdue | Pending | Jun 01, 2023 |
| 18039846 | OLIGONUCLEOTIDES | Oxford University Innovation Limited | OLSON, ALEXANDRA NADINE | 1684 | §102§103§112Other | Non-Final OA | 33d | Pending | Jun 01, 2023 |
| 18039813 | RNA-TARGETING COMPOSITIONS AND METHODS FOR TREATING CAG REPEAT DISEASES | Astellas Gene Therapies, Inc. | VIJAYARAGHAVAN, JAGAMYA NMN | 1637 | §103§112DP | Non-Final OA | — | Pending | Jun 01, 2023 |
| 18037795 | Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists | Zealand Pharma A/S | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103DP | Final Rejection | — | Pending | May 19, 2023 |
| 18199415 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. | STAVROU, CONSTANTINA E | 1632 | §112 | Final Rejection | — | Pending | May 19, 2023 |
| 18037597 | COMPUTER PROGRAM FOR TRAINING A NEUROLOGICAL CONDITION DETECTION ALGORITHM, METHOD OF PROGRAMMING AN IMPLANTABLE NEUROSTIMULATION DEVICE AND COMPUTER PROGRAM THEREFOR | Precisis GmbH | SCHLUETER, MARY GRACE | 3796 | §102§103§112 | Non-Final OA | — | Pending | May 18, 2023 |
| 18037196 | CYCLOTRON TARGET AND LANTHANUM THERANOSTIC PAIR FOR NUCLEAR MEDICINE | The Governors of the University of Alberta | DAVIS, SHARON M | 3646 | §103 | Non-Final OA | 35d overdue | Pending | May 16, 2023 |
| 18037117 | SYSTEM FOR SENSING EEG SIGNALS ON A LIVING BEING, AND SYSTEM FOR ELECTRICALLY STIMULATING TISSUE OF A LIVING BEING | Precisis GmbH | BERHANU, ETSUB D | 3791 | §101§103§112 | Final Rejection | 76d | Pending | May 16, 2023 |
| 18036720 | METHODS FOR PURIFYING INTER-ALPHA INHIBITOR PROTEINS | Prothera Biologics, Inc. | WALLENHORST, MAUREEN | 1797 | §112 | Non-Final OA | — | Pending | May 12, 2023 |
| 18196538 | MIR-375- AND MIR-1-REGULATED COXSACKIEVIRUS B3 HAS NO PANCREAS AND HEART TOXICITY BUT STRONG ANTITUMOR EFFICIENCY IN COLORECTAL CARCINOMAS | Technische Universität Berlin | SPENCE, JENNIFER SUZANNE | 1633 | §103 | Final Rejection | — | Pending | May 12, 2023 |
| 18035582 | POLYSACCHARIDES FOR IV ADMINISTRATION THAT TREAT SARS-COV-2 INFECTIONS | Pharmalectin, Inc. | CHO, DAVID H | 1693 | §103§112DP | Non-Final OA | — | Pending | May 05, 2023 |
| 18035442 | FILTER UNIT, TEXTILE TREATMENT APPARATUS AND METHOD | Xeros Limited | KURTZ, BENJAMIN M | 1711 | §102§103§112 | Non-Final OA | — | Pending | May 04, 2023 |
| 18140141 | METHODS OF TREATING LYMPHOPENIA | Keros Therapeutics, Inc. | KAUFMAN, CLAIRE M | 1674 | §102§103§112 | Non-Final OA | 60d | Pending | Apr 27, 2023 |
| 18034252 | PHARMACEUTICAL PACKAGES COMPRISING POLYPROPYLENE CONTAINERS AND NGF AQUEOUS FORMULATIONS PACKAGED THEREIN | Dompe' Farmaceutici Spa | SCHLIENTZ, NATHAN W | 1616 | §103 | Final Rejection | — | Pending | Apr 27, 2023 |
| 18031772 | USE OF N-MYRISTOYL TRANSFERASE (NMT) INHIBITORS IN THE TREATMENT OF CANCER, AUTOIMMUNE DISORDERS, AND INFLAMMATORY DISORDERS | Pacylex Pharmaceuticals Inc. | VALENROD, YEVGENY | 1628 | §102 | Non-Final OA | 34d | Pending | Apr 13, 2023 |
| 18030876 | PEPTIDE INHIBITORS OF GLIOMA-ASSOCIATED ONCOGENE DERIVED FROM THE COILED-COIL DIMERIZATION DOMAIN OF Kif7 | The General Hospital Corporation | REYNOLDS, FRED H | 1658 | §101§112 | Non-Final OA | — | Pending | Apr 07, 2023 |
| 18028025 | PRAME SPECIFIC T-CELL RECEPTORS AND USES THEREOF | Medigene Immunotherapies GmbH | BUTTICE, AUDREY L | 1647 | §112 | Final Rejection | 97d overdue | Pending | Mar 23, 2023 |
| 18027506 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. | ANDERSON, REBECCA L | 1626 | §102§103§112Other | Non-Final OA | — | Pending | Mar 21, 2023 |
| 18044747 | RIBITOL TREATMENT | The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health | NEAGU, IRINA | 1629 | §103§112DP | Non-Final OA | — | Pending | Mar 09, 2023 |
| 18024624 | PEPTIDES ENDOWED WITH ANGIOGENIC ACTIVITY | Dompe' Farmaceutici Spa | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §101§102§103§112 | Non-Final OA | 5d | Pending | Mar 03, 2023 |
| 18024182 | COMPOSITIONS AND METHODS FOR TREATING THERAPY RESISTANT CANCER | The General Hospital Corporation | SHIN, DANA H | 1635 | §102§103 | Non-Final OA | — | Pending | Mar 01, 2023 |
| 18024179 | METHODS FOR IDENTIFYING CROSS-MODAL FEATURES FROM SPATIALLY RESOLVED DATA SETS | The General Hospital Corporation | TRAN, DUY ANH | 2674 | §101§102§103Other | Non-Final OA | 132d overdue | Pending | Mar 01, 2023 |
| 18175224 | FILTRATION-BASED METHODS FOR PREPARING FETAL NUCLEATED RED BLOOD CELLS (NRBCS) FOR DIAGNOSTIC TESTING | Kellbenx Incorported | KIRWIN, STEFANIE JOHANNA | 1684 | §103 | Non-Final OA | — | Pending | Feb 27, 2023 |
| 18175225 | METHOD OF TREATMENT OF PATIENTS HAVING REDUCED SENSITIVITY TO A BCL-2 INHIBITOR | The Regents of the University of Colorado | KAUFMAN, CLAIRE M | 1674 | §102§103§112Other | Non-Final OA | — | Pending | Feb 27, 2023 |
| 18021979 | PEPTIDE FOR THERAPEUTIC APPLICATIONS IN THE DERMATOLOGICAL FIELD | Dompe' Farmaceutici S.p.A. | DONOGHUE, BRITTNEY ERIN | 1675 | §102§103 | Final Rejection | 14d | Pending | Feb 17, 2023 |
| 18165613 | CELL MEMBRANE PENETRATING CONJUGATES | Cygenica Limited | VARADARAJ, ARCHANA | 1658 | §101§102§103Other | Non-Final OA | 56d overdue | Pending | Feb 07, 2023 |
| 18019166 | METHODS FOR LEACHING AND RECOVERY OF PLATINUM GROUP METALS IN ORGANIC SOLVENTS | Excir Works Corp. | MCGUTHRY BANKS, TIMA MICHELE | 1733 | §112 | Final Rejection | 53d | Pending | Feb 01, 2023 |
| 18157453 | TREATMENT OF PELVIC ORGAN PROLAPSE | Remendium Labs LLC | KREMER, MATTHEW | 3791 | §112 | Non-Final OA | — | Pending | Jan 20, 2023 |
| 18016490 | INHIBITORS OF COMPLEMENT FACTOR C3 AND THEIR MEDICAL USES | Zp Spv 3 K/S | DABKOWSKI, ERINNE R | 1654 | §103§112DP | Non-Final OA | — | Pending | Jan 17, 2023 |
| 18154241 | METHODS AND COMPOSITIONS FOR TREATING EPILEPSY | Uniqure France | CHONG, KIMBERLY | 1636 | §112 | Final Rejection | — | Pending | Jan 13, 2023 |
| 18002368 | METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING ANTI-TL1A ANTIBODIES | Pfizer, Inc. | KAUFMAN, CLAIRE M | 1674 | §103§112 | Non-Final OA | — | Pending | Dec 19, 2022 |
| 18010513 | MATURED THREE-DIMENSIONAL PRINTED COMPOSITIONS AND USES THEREOF | Auregen Biotherapeutics SA | SCHUBERG, LAURA J | 1631 | §103 | Final Rejection | 37d overdue | Pending | Dec 15, 2022 |
| 18061755 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE | Invetx, Inc. | DAHLE, CHUN WU | 1641 | §103 | Final Rejection | 7d | Pending | Dec 05, 2022 |
| 18071388 | METHODS AND COMPOSITIONS FOR MAINTAINING AND EXPANDING HEMATOPOIETIC STEM CELLS | Trailhead Biosystems Inc. | TAKENAKA, RISA | 1632 | §103 | Final Rejection | 31d overdue | Pending | Nov 29, 2022 |
| 17924425 | POLYNUCLEOTIDE ARRAYS | Oxford University Innovation Limited | ZHANG, KAIJIANG | 1684 | §102 | Final Rejection | 30d overdue | Pending | Nov 10, 2022 |
| 17924578 | COMPOSITIONS AND METHODS FOR PROMOTING HAIR CELL REGENERATION | Decibel Therapeutics, Inc. | SINGH, ANOOP KUMAR | 1632 | §102§103§112 | Final Rejection | — | Pending | Nov 10, 2022 |
| 17920088 | HIGHLY-NETWORKED CORONAVIRUS IMMUNOGEN COMPOSITION | Massachusetts Eye And Ear Infirmary | SPENCER, ANDREA LYNNE MORRIS | 1631 | §102§103§112 | Non-Final OA | — | Pending | Oct 20, 2022 |
| 17996577 | TREATMENT OF VIRAL CONJUNCTIVITIS | Okogen, Inc. | FAN, LYNN Y | 1759 | §103 | Final Rejection | — | Pending | Oct 19, 2022 |
| 17913503 | COMPOSITIONS AND METHODS FOR DIABETES TREATMENT | The General Hospital Corporation | KANE, TREVOR LOGAN | 1657 | §103 | Final Rejection | — | Pending | Sep 22, 2022 |
| 17906631 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | Okogen, Inc. | SIFFORD, JEFFREY MARK | 1671 | §101§103§112Other | Non-Final OA | — | Pending | Sep 19, 2022 |
| 17909696 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INTRACELLULAR BACTERIAL INFECTIONS | Endolytix Technology, Inc. | KAMM, JUDITH MARIE | 1611 | §103§112Other | Final Rejection | 7d | Pending | Sep 06, 2022 |
| 17896781 | Methods and Compositions for Generating Human Forebrain Neural Progenitor Cells and for Maturation Thereof to Parvalbumin+ Interneurons | Trailhead Biosystems Inc. | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103§112 | Final Rejection | 14d | Pending | Aug 26, 2022 |
| 17800639 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Dompe' Farmaceutici Spa | LEE, ANDREW P | 1691 | §103 | Non-Final OA | 19d overdue | Pending | Aug 18, 2022 |
| 17819591 | PREPARATION AND COMPOSITION OF INTER-ALPHA INHIBITOR PROTEINS FROM HUMAN PLASMA FOR THERAPEUTIC USE | Prothera Biologics, Inc. | ORWIG, KEVIN S | 3991 | §103DP | Non-Final OA | 16d overdue | Pending | Aug 12, 2022 |
| 17798334 | CELL CULTURE MANAGEMENT SYSTEM | Integriculture Inc. | KRCHA, MATTHEW D | 1796 | §102§112 | Non-Final OA | 42d | Pending | Aug 09, 2022 |
| 17810197 | METHODS FOR SELECTIVE LEACHING AND EXTRACTION OF PRECIOUS METALS IN ORGANIC SOLVENTS | Excir Works Corp. | BAUM, ZACHARY JOHN | 1736 | §103 | Final Rejection | — | Pending | Jun 30, 2022 |
| 17810022 | METHODS FOR THE TREATMENT OF EPILEPSY | Centre National De La Recherche Scientifique | MEYERING, SHABANA SHABBEER | 1635 | §103 | Non-Final OA | 21d | Pending | Jun 30, 2022 |
| 17786360 | PREPARATION OF HALOGENATED ALKOXYETHANE | Commonwealth Scientific And Industrial Research Organisation | BAHTA, MEDHANIT W | 1692 | §103 | Final Rejection | 93d overdue | Pending | Jun 16, 2022 |
| 17831012 | COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF BABESIOSIS | Tufts Medical Center, Inc. | JACKSON-TONGUE, LAKIA J | 1645 | §102§112Other | Non-Final OA | — | Pending | Jun 02, 2022 |
| 17748323 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. | TRAN, KHOA NHAT | 1632 | §103 | Final Rejection | 10d overdue | Pending | May 19, 2022 |
| 17774338 | DIAGNOSIS AND TREATMENT OF NAFLD AND LIVER FIBROSIS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | WALLENHORST, MAUREEN | 1797 | §101§112 | Non-Final OA | — | Pending | May 04, 2022 |
| 17733509 | GASTROINTESTINAL IMPLANT DELIVERY SYSTEMS AND METHODS | Gi Dynamics, Inc. | ALEMAN, SARAH WEBB | 3774 | §103 | Final Rejection | — | Pending | Apr 29, 2022 |
| 17731112 | METHODS FOR ELECTRO-MECHANICAL TRANSFECTION | Kytopen Corporation | NOBLE, MARCIA STEPHENS | 1632 | §101§102§112Other | Non-Final OA | 9d | Pending | Apr 27, 2022 |
| 17771524 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CROHN'S DISEASE | Orchard Therapeutics (Europe) Limited | PERSONS, JENNA L | 1637 | §103§112 | Final Rejection | — | Pending | Apr 25, 2022 |
| 17768300 | COMPOSITIONS AND METHODS FOR MODIFYING EUKARYOTIC CELLS | Orchard Therapeutics (Europe) Limited | NOBLE, MARCIA STEPHENS | 1632 | §102§112 | Non-Final OA | 30d | Pending | Apr 12, 2022 |
| 17766280 | INHIBITOR OF CELL PROLIFERATION IN OBINUTUZUMAB RESISTANT CD20-POSITIVE CANCER, AND MEDICINAL COMPOSITION, MEDICINE, PRODUCTION, METHOD FOR INHIBITING CELL PROLIFERATION, THERAPEUTIC METHOD, TYPE II ANTI-CD20 ANTIBODY, COMPOUNDS, COMBINATION OF SAME, ENHANCER AND INDUCER, EACH RELATING THERETO | Chugai Seiyaku Kabushiki Kaisha | SANG, HONG | 1646 | §102§103§112 | Final Rejection | 29d | Pending | Apr 04, 2022 |
| 17765620 | DIAGNOSIS AND TREATMENT OF THYROID CANCER | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | GIAMMONA, FRANCESCA FILIPPA | 1681 | §103 | Non-Final OA | — | Pending | Mar 31, 2022 |
| 17764003 | METHODS FOR TREATING HYPERPHENYLALANINEMIA | Ptc Therapeutics Mp, Inc. | GAUGER, PAUL RANDALL | 1629 | §103DP | Final Rejection | 34d | Pending | Mar 25, 2022 |
| 17689117 | METHODS OF TREATING AND DIAGNOSING DISEASE USING BIOMARKERS FOR BCG THERAPY | The General Hospital Corporation | ABBAS, SYED JARAR | 1645 | §102§112 | Non-Final OA | 14d | Pending | Mar 08, 2022 |
| 17637392 | COMPSTATIN ANALOGUES AND THEIR MEDICAL USES | Zp Spv 3 K/S | COFFA, SERGIO | 1658 | §103 | Non-Final OA | 3d overdue | Pending | Feb 22, 2022 |
| 17629918 | ADOPTIVE TRANSFER OF PLASMACYTOID DENDRITIC CELLS TO PREVENT OR TREAT HAIR LOSS | Tufts Medical Center, Inc. | MIANO, JOSEPH PAUL | 1631 | §102§103§112 | Final Rejection | 134d overdue | Pending | Jan 25, 2022 |
| 17629313 | PEPTIDE HAVING HAIR GROWTH PROMOTING ACTIVITY, AND USE THEREOF | Caregen Co., Ltd. | NIEBAUER, RONALD T | 1658 | §101§112 | Final Rejection | 3d overdue | Pending | Jan 21, 2022 |
| 17628617 | COSMETIC COMPOSITIONS AND USES THEREOF | Alumier Labs, Inc. | JOHNSON, DANIELLE D | 1617 | §103§112 | Final Rejection | 57d | Pending | Jan 20, 2022 |
| 17627975 | SELF-ASSEMBLED VACCINES AND COMBINATION THERAPIES FOR TREATING CANCER | The General Hospital Corporation | LEE, YIE CHIA | 1642 | §103§112Other | Final Rejection | 78d | Pending | Jan 18, 2022 |
| 17625425 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | The Brigham And Women'S Hospital, Inc. | MCMILLIAN, KARA RENITA | 1623 | §102§112 | Final Rejection | — | Pending | Jan 07, 2022 |
| 17597351 | METHODS FOR THE TREATMENT OF EPILEPSY | Centre National De La Recherche Scientifique | MEYERING, SHABANA SHABBEER | 1635 | §103 | Final Rejection | 5d | Pending | Jan 04, 2022 |
| 17596491 | TARGETING DNA REPAIR IN TUMOR CELLS VIA INHIBITION OF ERCC1-XPF | The Governors of the University of Alberta | MARTIN, KEVIN STEPHEN | 1624 | §102§112 | Final Rejection | — | Pending | Dec 10, 2021 |
| 17440081 | CARDIOMYOCYTE PROLIFERATION | The Queensland Institute of Medical Research | TRAN, KHOA NHAT | 1632 | §103§112 | Final Rejection | 37d overdue | Pending | Sep 16, 2021 |
| 17427453 | ANTIMICROBIAL ENDOLYSIN POLYPEPTIDES, COMPOSITIONS AND FORMULATIONS | Axitan Holdings, Inc. | HELLMAN, KRISTINA M | 1654 | §112 | Final Rejection | 7d | Pending | Jul 30, 2021 |
| 17413223 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS ACROSS THE ROUND WINDOW MEMBRANE | Decibel Therapeutics, Inc. | REYNOLDS, FRED H | 1658 | §103 | Non-Final OA | 28d | Pending | Jun 11, 2021 |
| 17292107 | PATIENT-DERIVED AMYLOID XENOGRAFT NON-HUMAN ANIMAL MODEL | Neurimmune AG | LEVIN, JOEL D | 1633 | §103 | Final Rejection | 28d | Pending | May 07, 2021 |
| 17279691 | FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | Zealand Pharma A/S | BEANE, RANDALL L | 1654 | §103 | Final Rejection | 29d | Pending | Mar 25, 2021 |
| 17275266 | NANOPARTICLE FORMULATIONS AND METHODS OF THEIR USE | Children'S Medical Center Corporation | WAX, ROBERT A | 1615 | §103 | Non-Final OA | — | Pending | Mar 11, 2021 |
| 17257055 | COMPOSITIONS AND METHODS FOR REDUCTION OF LIPOPROTEIN A FORMATION AND TREATMENT OF AORTIC VALVE SCLEROSIS AND AORTIC STENOSIS | Abcentra, LLC | FONTAINHAS, AURORA M | 1675 | §103 | Final Rejection | 22d | Pending | Dec 30, 2020 |
| 16960221 | PROTON COUPLED ELECTROCHEMICAL CO2 CAPTURE SYSTEM | President and Fellows of Harvard College | KOLTONOW, ANDREW ROBERT | 1795 | §103§112 | Non-Final OA | — | Pending | Jul 06, 2020 |
| 16610357 | DEVICES AND METHODS FOR SENSOR-ENHANCED NEEDLE PLACEMENT | Rockport Medical Technologies LLC | DARB, HAMZA A. | 3783 | §103 | Non-Final OA | 77d overdue | Pending | Nov 01, 2019 |
| 16319849 | PEPTIDE-COATED CALCIUM PHOSPHATE PARTICLES | Cerapedics, Inc. | LEE, JIA-HAI | 1658 | §103DP | Final Rejection | — | Pending | Jan 23, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial